Open questions on bioequivalence: An updated reappraisal

Current Clinical Pharmacology

Volumn 2, Issue 2, 2007, Pages 179-189

  Marzo, Antonio ^a  

^a IPAS SA   (Switzerland)

Author keywords

Bioequivalence; Clinical trials; Guidelines

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AURANOFIN; CANRENONE; CARBAMAZEPINE; CHLOROQUINE; CLOZAPINE; CYCLOSPORIN; CYTOSTATIC AGENT; DIGITOXIN; DRUG METABOLITE; ENCAINIDE; FLUTAMIDE; GENERIC DRUG; MEFLOQUINE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; NORFLUOXETINE; NORTAMOXIFEN; PENTAMIDINE; SALICYLIC ACID; SIMVASTATIN; SPIRONOLACTONE; TAMOXIFEN; TAMSULOSIN; UNINDEXED DRUG; WARFARIN; ZOFENOPRIL; ZOFENOPRILAT;

BIOEQUIVALENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMMERCIAL PHENOMENA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MARKETING; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; FORGERY; GENETIC POLYMORPHISM; GYNECOMASTIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID DIET; LIQUID CHROMATOGRAPHY; MEDICAL ETHICS; MEDICAL LITERATURE; ORTHOSTATIC HYPOTENSION; PERSONAL EXPERIENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; REPEATED DRUG DOSE; RESPIRATORY TRACT DISEASE; REVIEW; SINGLE DRUG DOSE; SOUTHERN EUROPE; SYNCOPE; TANDEM MASS SPECTROMETRY; UNITED STATES; UNSPECIFIED SIDE EFFECT; VOMITING;

ADMINISTRATION, TOPICAL; ANIMALS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUGS, GENERIC; FOOD-DRUG INTERACTIONS; HUMANS; PHARMACOKINETICS; THERAPEUTIC EQUIVALENCY;

EID: 34249288322     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488407780598144     Document Type: Review

References (94)

1. CPMP working party of medicinal products. Note for guidance: investigation of bioavailability and bioequivalence. III/54/89 EN; December 1991.
2. EMEA Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98; July 2001.
3. Bioavailability and bioequivalence studies for orally administered drug products: general conditions. FDA, Center for Drug Evaluation and Research; July 11, 2002. Available from URL: http://www.fda.gov/OHRMS/ DOCKETS/98fr/071102e.pdf [Accessed 2003 Sep 9].
4. In vivo bioequivalence guidelines: US FDA Pharmacopoeia XXIII 1998 (Suppl.8): 4382-4426.
5. Marzo A. Open questions on bioequivalence. Pharmacol Res 1995; 32: 237-240.
6. Marzo A, Balant LP. The bioequivalence: an updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Arzneim Forsch 1995; 45: 109-115.
7. Marzo A. Pharmacokinetic analysis, bioavailability and operating guidelines. J Pharm Pharmacol 1997; 49: 1259-1260.
8. Marzo A. Crossover design in tamoxifen bioequivalence: a borderline situation. J Pharm Pharmacol 1998; 50: 1433-1434.
9. Marzo A. Open questions on bioequivalence: some problems and some solutions. Pharmacol Res 1999; 40: 357-368.
10. Marzo A, Ceppi Monti N, Vuksic D. Experimental, extrapolated and truncated AUC in bioequivalence trials. Eur J Clin Pharmacol 1999; 55: 627-631.
11. Marzo A, Vuksic D, Crivelli F. Bioequivalence of endogenous substances facing homeostatic equilibria: an example with potassium. Pharmacol Res 2000; 42: 523-525.
12. Marzo A. Bioequivalence behind the scenes. Pharm Dev Reg 2003; 1: 179-189.
13. Marzo A, Reiner V. Open questions on bioequivalence: the case of multiple peak phenomenon. J Pharm Pharmacol 2004; 56: 281-282.
14. Marzo A, Ceppi Monti N. Acceptable and unacceptable procedures in bioavailability and bioequivalence trials. Pharmacol Res 1998; 38: 401-404.
15. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine 10, 11-epoxide. Clin Pharmacokinet 1986; 11: 177-198.
16. Bennett WM, Pulliam JP. Cyclosporine nephrotoxicity. Ann Intern Med 1983; 99: 851-854.
17. Jacobo E, Schmidt JD, Weinstein SH, et al. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology 1976; 8: 213-233.
18. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behaviour after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990; 47: 12-19.
19. Palareti G, Legnani C. Warfarin withdrawal: pharmacokinetic/ pharmacodynamic considerations. Clin Pharmacokinet 1996; 30: 300-313.
20. Pokorny R, Finkel MJ, Robinson WT. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm Res 1994;11: 1221.
21. Meyer MC. United States food and drug administration requirements for approval of generic drug products. J Clin Psychiatry 2001; 62(Suppl.5): 4-9.
22. Cutler NR. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. J Clin Psychiatry 2001; 62(Suppl 5): 10-13.
23. Marzo A. Clinical pharmacokinetic registration file for NDA and ANDA procedures. Pharmacol Res 1997; 36: 425-450.
24. Marzo A. Toxicokinetics of endogenous substances: a neglected issue. Arzneim Forsch 1996; 46: 1-10.
25. Marzo A, Rescigno A. Pharmacokinetics of endogenous substances: some problems and some solutions. Eur J Drug Metab Pharmacokinet 1993; 18: 77-88.
26. Dong BJ, Hauck WW, Gambertoglio JG, et al. Bioequivalence of generic and brand-name levothyroxine product in the treatment of hypothyroidism. JAMA 1997; 277: 1205-1213.
27. Cerutti R, Rivolta G, Cavalieri L, et al. Bioequivalence of levothyroxine tablets administered in target population in steady state. Pharmacol Res 1999; 39: 193-201.
28. Scotti A, Bianchini C, Abbiati G, Marzo A. Absorption of calcium administered alone or in fixed combination with vitamin D to healthy volunteers. Arzneim Forsch 2001; 51: 493-500.
29. Marzo A, Dal Bo L, Mazzucchelli P, et al. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers. Arzneim Forsch 2002; 52: 233-242.
30. Schulz M, Schmoldt A, Donn F, Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol 1988; 34: 633-636.
31. Walter-Sack I, de Vries JX, Kreiner C, et al. Bioequivalence of allopurinol preparations: to be assayed by parent drug or the active metabolite? Clin Invest 1993; 71: 240-246.
32. Garteiz DA, Hook RH, Walker BJ, Okerholm RA. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittel Forschung 1982; 32: 1185-1190.
33. Chen XY, Zhong DF, Duan JL, Yan BX. LC-MS-MS analysis of 2-pyridylacetic acid, a major metabolite of betahistine: application to a pharmacokinetic study in healthy volunteers. Xenobiotica 2003; 33: 1261-1771.
34. Bochner F, Lloyd JV. Aspirin for myocardial infarction: clinical pharmacokinetic considerations. Clin Pharmacokinet 1995; 28: 433-438.
35. Marzo P, Scaglione F. Antiplatelet and other anti-inflammatory activities of acetylsalicylic acid: mechanisms of action, expectations and therapeutic relevance. Int Med 2000; 8: 1-4.
36. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci 1990; 47: 579-585.
37. Kearney AS, Crawford LF, Mehta SC, Radebaugh GW. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, Cl-981. Pharm Res 1993; 10: 1461-1465.
38. Wingard Jr LB, O'Reilly RA, Levy G. Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations. Clin Pharmacol Ther 1978; 23: 212-217.
39. Gibson TP, Dobrinska MR, Lin JH, Entwistle LA, Davies RO. Biotranformation of sulindac in endstage renal disease. Clin Pharmacol Ther 1987; 42: 82-88.
40. Woosley RL, Wood AJ, Roden DM. Drug therapy: encainide. N Engl J Med 1988; 318: 1107-1115.
41. Froemming JS, Lam YW, Jann MW, Davis CM. Pharmacokinetics of haloperidol. Clin Pharmacokinet 1989; 17: 396-423.
42. Chabner BA, Allegra CJ, Curt GA, et al. Antineoplastic agents. In: Hardmann GJ, Limbird LE, Molinoff PB, et al. Eds. The pharmacological basis of therapeutics. 9th ed., New York: McGraw-Hill 1996; 1233-1287.
43. Shah VP, Midha KK, Findlay JWA, et al. Bioanalytical method validation. A revisit with a decade of progress. Pharm Res 2000; 17: 1551-1557.
44. Dal Bo L, Mazzucchelli P, Marzo A. Assay of zofenopril and its active metabolite zofenoprilat by liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B 2000; 749: 287-294.
45. Dal Bo L, Mazzucchelli P, Marzo A. A high sensitive bioassay of lidocaine in human plasma by LC-MS-MS. J Chromatogr A 1999; 854: 3-11.
46. Marzo A, Ceppi Monti N, Crivelli F, et al. Systemic bioavailability of benzydamine mouthwash in two different salification forms. Fourth European Congress of Pharmaceutical Sciences, Milan, September 11-13, 1998. Eur J Pharm Sci 1998; 6(Suppl 1): S89 (abstract 355).
47. Marzo A, Dal Bo L, Mazzuchelli P, et al. Amlodipine bioequivalence achieved with a very sensitive liquid chromatography tandem mass spectrometric bioassay. Arzneim Forsch 2000; 50: 688-694.
48. Marzo A, Meoli A, Pezzuto D, et al. Bioequivalence of inhaled formoterol fumarate assessed from pharmacodynamic safety, and pharmacokinetic data. Arzneim Forsch 2000; 50: 559-563.
49. Iacobelli M, Clerici G, Marzo A, et al. A comparative bioavailability study of two formulations of calcium heparin. Int Med 1998; 6: 39-44.
50. Marzo A, Curti S. L-carnitine moiety assay: an up-to-date reappraisal covering the commonest methods for various applications. J Chromatogr 1997; 702: 1-20.
51. Marzo A, Cardace G, Arrigoni Mastelli E. Enzymes in seteroselective pharmacokinetics of endogenous substances. Chirality 1992; 4: 247-251.
52. Keller T, Cambon N, Genevray M, et al. Bioequivalence study of fluoxetine hydrochloride in healthy volunteers. Arzneim Forsch 2005; 55: 491-497.
53. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999; 36: 315-328.
54. 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J Pharm Sci 2002; 91: 32-40.
55. Scalbert A, Morand C, Manach C, Remsey C. Absorption and metabolism of polyphenols in the gut and impact on health. Biomed Pharmacother 2002; 56: 276-282.
56. Fourtillan JB, Bubourg D. Etude pharmacocinétique du piroxicam chez l'homme sain, après admnistration d'une dose égale à 20 mg par voie orale. Thérapie 1983; 38: 163-170.
57. Brogden RN, Heel RC, Speight TM, Avery GS. Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy. Drugs 1984; 28: 292-323.
58. Ikegami H, Shima K, Tanaka A, Tahara Y, Hirota M, Kumahara Y. Interindividual variation in the absorption of glibenclamide in man. Acta Endocrinol 1986;111: 528-532.
59. Balan G, Timmins P, Greene DS, Marathe PH. In vitro in-vivo correlation models for glibenclamide after administration of metformin/ glibenclamide tablets to healthy human volunteers. J Pharm Pharmacol 2000; 52: 831-838.
60. Parquet M, Metman EH, Raizman A, Rambaud JC, Berthaux N, Infante R. Bioavailability, gastrointestinal transit, solubilization and faecal excretion of ursodeoxychoolic acid in man. Eur J Clin Invest 1985; 15: 171-178.
61. Somogyi A, Gugler R. Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet 1983; 8: 463-495.
62. Chan KH, Mojaverian P, Ziehmer BA. John VA. Application of radiotelemetric technique in evaluating diclofenac sodium absorption after oral administration of various dosage forms in healthy volunteers. Pharm Res 1990; 7: 1026-1032.
63. Terhaag B, Gramatte T, Hrdlcka P, Richter K, Feller K. The influence of food on the absortpion of diclofenac as a pure substance. Int J Clin Pharmacol Ther Toxicol 1991; 29: 418-421.
64. Terhaag B, Hoffmann A, Barkworth M, Vens-Cappell B. Bioavailability of a new effervescent tablet of diclofenac. Int J Clin Pharmacol Ther 2000; 38: 546-551.
65. Marzo A, Dal Bo L, Verga F, et al. Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. Arzneim Forsch 2000;50: 43-47.
66. Macia MA, Frias J, Carcas AJ, Guerra P, Valiente R, Lucero ML. Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. Int J Clin Pharmacol Ther 1995; 33: 333-339.
67. Reiner V, Reiner A, Reiner G, Conti M. Increased absorption rate of diclofenac from fast acting formulations containing ist potassium salt. Arzneimittelforschung 2001; 51: 885-890.
68. Bettini R, Giordano F, Donini C, et al. Swelling force development as a result of hydrate formation in diclofenac sodium or nitrofurantoin tablets. STP Pharm Sci 2000; 10: 335-339.
69. EMEA. Note for guidance on modified-release oral and transdermal dosage forms. CPMP/EWP/280/96; July 28, 1999.
70. Marzo A, Heftmann E. Enantioselective analytical methods in pharmacokinetics with specific references to genetic polymorphic metabolism. J Biochem Biophys Methods 2002; 54: 57-70.
71. Marzo A, Dal Bo L, Mazzucchelli P, et al. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneim Forsch 1999; 49: 992-996.
72. Cattaneo C, Caccia C, Marzo A, Maj R, Fariello RG. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine-oxidase B inhibition. Clin Neuropharmacol 2003; 26: 213-217.
73. Marzo A, Dal Bo L, Ceppi Monti N, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 2004; 50: 77-85.
74. Marzo A, Ceppi Monti N, Giusti A, Abbiati G, Parenti M. Pharmacokinetic behaviour of antihrombin III following intravenous infusion in healthy volunteers. Arzneim Forsch 2002; 52: 187-193.
75. Marzo A. Incoming guidelines on chirality: a challenge for pharmacokinetics in drug development. Arzneim Forsch 1994; 44: 791-793.
76. Massoomi F, Savage J, Destache CJ. Omeprazole: a comprehensive review. Pharmacotherapy 1993; 13: 46-59.
77. CMPM working party on quality, safety, efficacy of medicinal products. Note for guidance: investigation on chiral active substances. III 3601/ 91-EN; October 1993.
78. Marzo A, Fibbioli M, Marone C, Cerutti B. The degree of predictivity in pilot studies on six subjects in bioequivalence trials. Pharmacol Res 2004; 49: 283-286.
79. Weidekamm E, Rüsing G, Captain H, Sorgel F, Crevoisier C. Lack of bioequivalence of a generic mefloquine tablet with the stadard product. Eur J Clin Pharmacol 1998; 54: 615-619.
80. Lam YWF, Ereshefsky L, Toney G, Gonzales C. Branded Versus Generic Clozapine: Bioavailability Comparison and Interchangeability Issues. J Clin Psychiatry 2001; 62(Suppl 5): 18-22.
81. Joshi MV, Gokhale PC, Pohujani SM, Dalvi SS, Karandikar SM, Kshirsagar NA. Bioinequivalence of marketed diltiazem preparations. Eur J Clin Pharmacol 1990; 39: 189-190.
82. Beermann B, Groschinsky-Grind M, Lindstrôm B. Bioavailability of two hydrochlorothiazide preaparations. Eur J Clin Pharmacol 1977; 11: 203-205.
83. Locniskar A, Greenblatt DJ, Harmatz JS, Shader RI. Bioinequivalence of a generic brand of diazepam. Biopharm Drug Dispos 1989; 10: 597-605.
84. Meyer MC, Straughn AB, Jarvi EJ, Wood GC, Pelsor FR, Shah VP. The bioinequivalence of carbamazepine tablets with a history of clinical failure. Pharm Res 1992; 9: 1612-1616.
85. Adams WP, Hasegawa J, Johnson RN, Haring RC. Conjugated estrogens bioinequivalence: comparison of four products in postmenopausal women. J Pharm Sci 1979; 68: 986-991.
86. Lindenbaum J, Mellow MH, Blackstone MO, Butler VP Jr. Variation in biologic availability of digoxin from four preparations. N Engl J Med 1971; 24: 1344-1347.
87. Gleiter CH, Gundert-Remy U. Bioinequivalence and drug toxicity. How great is the problem and what can be done? Drug Saf 1994; 11: 1-6.
88. Marzo A, Fibbioli M. Could publication of bioinequivalence data discourage frauds on bioequivalence trials? Clin Res Reg Affairs 2002; 19: 63-66.
89. Latini R, Rognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984; 9: 136-156.
90. Blocka KL, Paulus HE, Furst DE. Clinical pharmacokinetics of oral and injectable gold compounds. Clin Pharmacokinet 1986; 11: 133-143.
91. White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 1985; 10: 187-215.
92. Mooradian AD. Digitalis: an updated of clinical pharmacokinetics, therapeutic monitoring techniques, and treatment recommendations. Clin Pharmacokinet 1988; 15: 165-179.
93. Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 1990; 19(4): 264-279.
94. Bronner U, Gastafsson LL, Doua F, et al. Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with Trypanosoma gambiense sleeping sickness. Br J Clin Pharmacol 1995; 39: 289-295.